High Potency API/HPAPI Market analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).
High Potency API /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech (Biologic, Biosimilar)), Manufacturer (Captive, Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecast to 2021
High Potency API /HPAPI Market Stakeholders:
- Manufacturers of HPAPIs
- Distributors and suppliers of HPAPIs
- Potential investors in the HPAPIs market
- Pharmaceutical companies
- Biotechnology companies
- Contract manufacturing organizations
- Life science research centers
- Healthcare payers
High Potency Active Pharmaceutical Ingredients Market, by Type of Manufacturer Get Sample Copy Here@ www.reportsnreports.com/contacts/r….aspx?name=828055
The global high potency active pharmaceutical ingredients (HPAPI) market is expected to reach USD 24.09 billion by 2021 from USD 16.02 billion in 2016, growing at a CAGR of 8.5% from 2016 to 2021. This market is categorized on the basis of type, type of manufacturer, type of synthesis, therapeutic application, and region.
Major factors contributing to the growth of the high potency rapid growth in the oncology drugs market, increasing focus of pharmaceutical companies on HPAPIs, and advancements in HPAPI technologies. Growing demand for antibody drug conjugates also provide an impetus for the growth of this market.
Their high specificity of action, has caused ACDs to gain significant attention, resulting in a noteworthy increase in the number of ADCs under development. Considering the growing opportunities in this market, many companies are making significant investments for the development of novel ACDs.
In October 2015, ADC Biotechnology (U.K.) invested USD 10 million to build a manufacturing facility for advanced anticancer drugs. Many companies are also cross collaborating for research in the development of next-generation ADCs.
For example, in June 2014, Merck Serono entered into a collaboration with Mersana Therapeutics Inc. for the development of next-generation ADCs.
Emerging markets have opened an array of opportunities for the high potency active pharmaceutical ingredients market. Moreover, the market also offers lucrative opportunities for CMOs and CDMOs.
However, factors such as astringent regulatory requirements and requirement of large investments may restrain the growth of this market.
Access High Potency API /HPAPI Market 2017-2021 spreads across 214 pages profiling 11 companies and supported with 221 tables and 44 figures available at www.reportsnreports.com/contacts/d…aspx?name=828055
High Potency Active Pharmaceutical Ingredients Market, By Type of Manufacturer
Merchant HPAPI Manufacturers Market, By Type
Innovative Merchant HPAPI Manufacturers
Generic Merchant HPAPI Manufacturers
Merchant HPAPI Manufacturers Market, By Type of Synthesis
High Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application (Page No. - 93)10.1 Introduction
Other Therapeutic Applications
Fundamental from Table of Content
3 Executive Summary
4 Premium Insights
4.1 High Potency Active Pharmaceutical Ingredients Market Overview
4.2 High Potency Active Pharmaceutical Ingredients Market, By Type
4.3 High Potency Active Pharmaceutical Ingredients Market, By Type of Synthesis
4.4 High Potency Active Pharmaceutical Ingredients Market, By Therapeutic Area
4.5 High Potency Active Pharmaceutical Ingredients Market: Geographic Snapshot
13 Company Profiles
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, RnRMR View)*
13.2 Pfizer, Inc.
13.3 Novartis International AG
13.5 F. Hoffmann-La Roche Ltd.
13.6 Bristol-Myers Squibb
13.7 Boehringer Ingelheim
13.8 Teva Pharmaceutical Industries Ltd.
13.9 ELI Lilly and Company
13.10 Merck & Co., Inc.
13.11 Abbvie Inc.
13.12 Mylan N.V.
*Details on RnR View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.
Access report at www.reportsnreports.com/purchase.aspx?name=828055